Cargando…

Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid

5,6-Dimethylxanthenone-4-acetic acid, synthesised in this laboratory, reduces tumour blood flow, both in mice and in patients on Phase I trial. We used TUNEL (TdT-mediated dUTP nick end labelling) assays to investigate whether apoptosis induction was involved in its antivascular effect. 5,6-Dimethyl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ching, L-M, Cao, Z, Kieda, C, Zwain, S, Jameson, M B, Baguley, B C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2002
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375421/ https://www.ncbi.nlm.nih.gov/pubmed/12085190 http://dx.doi.org/10.1038/sj.bjc.6600368

Ejemplares similares

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
por: Ching, L-M, et al.
Publicado: (2004)

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
por: Zhao, L, et al.
Publicado: (2002)

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
por: Jameson, M B, et al.
Publicado: (2003)

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
por: Lash, C. J., et al.
Publicado: (1998)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
por: Rustin, G J S, et al.
Publicado: (2003)

Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice.
por: Ching, L. M., et al.
Publicado: (1992)

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
por: Ching, L. M., et al.
Publicado: (1995)

Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
por: Philpott, M., et al.
Publicado: (1997)

Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.
por: Laws, A. L., et al.
Publicado: (1995)

Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
por: Ching, L. M., et al.
Publicado: (1998)

Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
por: Cao, Z, et al.
Publicado: (1999)

Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.
por: Moilanen, E., et al.
Publicado: (1998)

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
por: Wildiers, H, et al.
Publicado: (2003)

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging
por: Robinson, S P, et al.
Publicado: (2003)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid.
por: Zwi, L. J., et al.
Publicado: (1990)

Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study
por: Pahernik, S, et al.
Publicado: (2002)

The Use of Antivascular Endothelial Growth Factor Agents in the Perioperative Period in Diabetic Vitrectomy
por: Abu-Yaghi, Nakhleh E., et al.
Publicado: (2012)

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
por: Zampros, Ilias, et al.
Publicado: (2012)

Promising Novel Treatment against Keloids: Antivascular Endothelial Growth Factor Agents
por: Abtahi-Naeini, Bahareh, et al.
Publicado: (2019)

Commentary: Antivascular endothelial growth factor and retinopathy of prematurity
por: Dudani, Ajay Indur, et al.
Publicado: (2019)

Commentary: Ziv-aflibercept: An alternative antivascular endothelial growth factor agent for polypoidal choroidal vasculopathy
por: Anshuman, Kumar, et al.
Publicado: (2019)

Inhibition of growth and induction of apoptosis in human breast cancer by transfection of gef gene
por: Boulaiz, H, et al.
Publicado: (2003)

Use of antivascular endothelial growth factor for diabetic macular edema
por: Karim, Rushmia, et al.
Publicado: (2010)

Apoptosis induction in renal cell carcinoma by TRAIL and γ-radiation is impaired by deficient caspase-9 cleavage
por: Ramp, U, et al.
Publicado: (2003)

PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells
por: Maginn, E N, et al.
Publicado: (2011)

Induction of DNA breaks and apoptosis in crosslink-hypersensitive V79 cells by the cytostatic drug β-D-glucosyl-ifosfamide mustard
por: Becker, R, et al.
Publicado: (2002)

Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells
por: Rauca, Valentin-Florian, et al.
Publicado: (2018)

Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach
por: Pan, Shu-Ting, et al.
Publicado: (2015)

The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction
por: Descamps, G, et al.
Publicado: (2012)

Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity
por: Jamieson, S M F, et al.
Publicado: (2003)

Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells
por: Akagi, M, et al.
Publicado: (2003)

BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma
por: Bodet, L, et al.
Publicado: (2010)

Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells
por: Ucur, E, et al.
Publicado: (2003)

α-Tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells
por: Tomasetti, M, et al.
Publicado: (2004)

Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection
por: Eser, Alexander, et al.
Publicado: (2020)

Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor
por: Sassa, Yukio, et al.
Publicado: (2010)

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
por: Tranos, Paris, et al.
Publicado: (2013)

An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway
por: Chen, G, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v2bpl58lcnd7fg9iruqvi92to2